Low- versus standard-dose alteplase in acute lacunar ischemic stroke: the ENCHANTED trial - online supplemental

Objective: To determine any differential efficacy and safety of low- versus standard-dose intravenous alteplase for lacunar versus non-lacunar acute ischemic stroke (AIS), we performed post-hoc analyzes from the Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED) alteplase dose-arm. Methods: In a cohort of 3297 ENCHANTED participants, we identified those with lacunar or non-lacunar AIS with different levels of confidence (definite/probable/possible) according to pre-specified definitions based on clinical and adjudicated imaging findings. Logistic regression models were used to determine associations of lacunar AIS with 90-day outcomes (primary, modified Rankin scale [mRS] scores 2-6; secondary, other mRS scores, intracerebral hemorrhage [ICH], and early neurologic deterioration [END] or death) and treatment effects of low- versus standard-dose alteplase across lacunar and non-lacunar AIS with adjustment for baseline covariables. Results: Of 2588 participants with available imaging and clinical data, we classified cases as definite/probable lacunar (n=490) or non-lacunar AIS (n=2098) for primary analyses. Regardless of alteplase dose received, lacunar AIS participants had favorable functional (mRS 2-6, adjusted odds ratio [95% CI] 0.60 [0.47-0.77]) and other clinical or safety outcomes, compared to participants with non-lacunar AIS. Low-dose alteplase (versus standard) had no differential effect on functional outcomes (mRS 2-6, 1.04 [0.87-1.24]) but reduced the risk of symptomatic ICH in all included participants. There were no differential treatment effects of low- versus standard-dose alteplase on all outcomes across lacunar and non-lacunar AIS (all Pinteraction ≥0.07). Conclusions: We found no evidence from the ENCHANTED trial that low-dose alteplase had any advantages over standard-dose for definite/probable lacunar AIS.Funding provided by: The National Health and Medical Research Council (NHMRC) of Australia*Crossref Funder Registry ID: Award Number: 1020462 and 1101113Funding provided by: The Stroke Association of the UK*Crossref Funder Registry ID: Award Number: TSA 2012/01 and 2015/01Funding provided by: The Ministry of Health and the National Council for Scientific and Technological Development of Brazil *Crossref Funder Registry ID: Award Number: CNPQ: 467322/2014-7, 402388/2013-5Funding provided by: The Ministry for Health, Welfare and Family Affairs of the Republic of Korea *Crossref Funder Registry ID: Award Number: HI14C1985Funding provided by: A research grant from Takeda for conduct of the study in China*Crossref Funder Registry ID: Award Number: N